Status: Enrolling
Investigator: Shilpan Shah
Study Coordinator: Danielle Grbavac
Phone: 346.238.4456
The purpose of this study is to compare the efficacy and safety of fixed duration pirtobruitinib (LOXO-305) with VR (Arm A) compared to VR alone (Arm B) in patients with CLL/SLL who have been previously treated with at least one prior line of th ... Read more >
